Search
Close this search box.

News

Terumo Aortic announces publication of the primary endpoint results from the TREO Pivotal Study

Terumo Aortic announced today the publication of the primary endpoint results from the investigational device exemption (IDE) pivotal study in the Journal of Vascular Surgery.

Following recent approval by the US Food and Drug Administration (FDA) of the TREO® Abdominal Aortic Stent-Graft System for the treatment of patients with abdominal aortic aneurysms (AAA), Terumo Aortic announced today the publication of the primary endpoint results from the investigational device exemption (IDE) pivotal study in the Journal of Vascular Surgery.

Over a three-year period, a multicentre, non-randomised, investigational device exemption (IDE) pivotal study assessed the safety and effectiveness of TREO®. A total of 150 patients with infrarenal abdominal aortic or aorto-iliac aneurysms were treated in 29 centres across the United States. Follow-up continues but the primary safety and effectiveness endpoint analysis is now complete and demonstrated 100% technical success, only 0.7% incidence of major adverse events at 30 days, and 93.1% successful aneurysm treatment at one year.

In line with previous studies such as the global RATIONALE registry, a high percentage of patients had positive aortic remodeling with 54.3% who had aneurysm sac shrinkage > 5 mm at three years.

Principal investigator of the study and author, Matthew J. Eagleton, MD (Chief, Division of Vascular and Endovascular Surgery and Co-Director, Fireman Vascular Center, Massachusetts General Hospital, Boston, US) commented: “TREO® is a new generation EVAR device designed to improve deployment and fixation, and increase the potential to treat more complex aortas with a wider range of sizing options and a number of engineering features to ensure durability for better longer-term outcomes. Research continues with ongoing follow-up of the IDE cohort for a maximum of 10 years.”

One of the authors of the study, Michael C. Stoner, MD (Professor and Chief, Vascular Surgery, University of Rochester, New York, US) commented on the consistently good sac regression observed with TREO® saying: “Worldwide experience with this device along with publications from our groups have already suggested that TREO is linked to positive remodeling. Certainly, data to three years in the IDE study are in line with those earlier findings and, as we gain more experience with TREO, it will be beneficial to develop an even better understanding of the physiological factors contributing to sac regression.”

Latest news

Contact us

Click the button below to get in touch. For more updates, follow us on X and LinkedIn. You can also view our VuMedi channel. 

Latest news

Subscribe for Email Updates

Your subscription could not be saved. Please try again.
Please check your email to confirm your subscription.

Subscribe to our regular email news to keep you updated on the latest information and events from Terumo Aortic.

We use Brevo as our marketing platform. By clicking below to submit this form, you acknowledge that the information you provided will be transferred to Brevo for processing in accordance with their terms of use

REGISTRATION FORM

AATS - Hands on Training - Registration

Personal Details

Thoraflex Hybrid Product Overview - Delivered Andrew Easton & Ryan Martin.

Sunday 28th April: 09:00 - 09:30
Session 1 Checkbox
Spaces Remaining: 8

This session is now fully booked.

Adaptability & Versatility of Thoraflex Hybrid - Pedro Catarino, MD.

Sunday 28th April: 12:15 - 13:15
Session 2 Checkbox
Spaces Remaining: 8

This session is now fully booked.

Thoraflex Hybrid Product Overview - Delivered Andrew Easton & Ryan Martin.

Sunday 28th April: 15:45 - 16:15
Session 3 Checkbox
Spaces Remaining: 8

This session is now fully booked.

Thoraflex Hybrid Product Overview - Delivered Andrew Easton & Ryan Martin.

Monday 29th April: 09:15 - 09:45
Session 4 Checkbox
Spaces Remaining: 8

This session is now fully booked.

Thoraflex Hybrid - The Canadian Experience - Michael Chu, MD.

Monday 29th April: 12:15 - 13:15
Session 5 Checkbox
Spaces Remaining: 8

This session is now fully booked.

Disclaimer:
We collect your personal information for the sole purpose of managing event attendees and ensuring the smooth operation of the AATS event. Your data will not be used for marketing purposes unless you have explicitly signed up for updates or promotional materials.

REGISTRATION FORM

Charing Cross - Hands on Training - Registration

Personal Details

Fenestrated TREO Demo - Lukasz Siudmiak

Tuesday 23rd April: 10:30 - 11:30
Session 1 Checkbox
Spaces Remaining: 7

This session is now fully booked.

TREO Fit Mini-Symposia - Prof Vladimir Makaloski

Tuesday 23rd April: 13:30 - 14:30
Session 2 Checkbox
Spaces Remaining: 8

This session is now fully booked.

Fenestrated TREO Mini Symposium - Prof Van Herwaarden

Tuesday 23rd April: 15:00 - 16:00
Session 3 Checkbox
Spaces Remaining: 8

This session is now fully booked.

RelayBranch Demo - Lukasz Siudmiak

Tuesday 23rd April: 16:30 - 17:30
Session 4 Checkbox
Spaces Remaining: 8

This session is now fully booked.

Fenestrated TREO Demo - Lukasz Siudmiak

Wednesday 24th April: 10:30 - 11:30
Session 5 Checkbox
Spaces Remaining: 8

This session is now fully booked.

Thoracoflo Mini Symposium - Prof Sabine Wipper

Wednesday 24th April: 13:30 - 14:30
Session 6 Checkbox
Spaces Remaining: 8

This session is now fully booked.

Fenestrated TREO Demo - Lukasz Siudmiak

Wednesday 24th April: 15:00 - 16:00
Session 7 Checkbox
Spaces Remaining: 8

This session is now fully booked.

TEVAR Custom Made Demo - Lukasz Siudmiak

Wednesday 24th April: 16:30 - 17:30
Session 8 Checkbox
Spaces Remaining: 8

This session is now fully booked.

TEVAR Custom Made Demo - Lukasz Siudmiak

Thursday 25th April: 10:30 - 11:30
Session 9 Checkbox
Spaces Remaining: 8

This session is now fully booked.

Disclaimer:
We collect your personal information for the sole purpose of managing event attendees and ensuring the smooth operation of the AATS event. Your data will not be used for marketing purposes unless you have explicitly signed up for updates or promotional materials.